Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides an overview of the prognostic factors that can influence the outcomes of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Prior to infusion, critical prognostic factors include age, comorbidities, performance status, and disease characteristics (lactate dehydrogenase level, total metabolic tumor burden, levels of inflammatory markers). Different CAR-T products vary in efficacy and cellular composition, impacting patient outcomes. In the post-infusion setting, the early disease response and measurable residual disease (MRD) status predict the long-term outcomes of the therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.